Quality assurance methodology for Varian RapidArc treatment plans

Ileana Iftimia, Eileen T. Cirino, Li Xiong, Herbert W. MowerJournal of Applied Clinical Medical Physics 2010 · DOI

TL;DR

This paper presents a robust methodology for patient-specific quality assurance (QA) of Varian RapidArc treatment plans, a novel arc-based radiotherapy technique. The authors demonstrate that their approach, using a 2D diode array and an ion chamber, achieves high agreement between calculated and measured doses, ensuring treatment accuracy and patient safety.

What Problem Does This Paper Address?

Varian's RapidArc technology offers faster and potentially more precise radiation delivery by using a single, continuous arc. However, this novel approach introduces complexities in treatment planning and delivery that necessitate rigorous patient-specific quality assurance (QA) to ensure accuracy. Traditional QA methods, often designed for static beam delivery, may not fully capture the nuances of arc-based treatments, such as rotational geometry and varying dose rates. The authors identified a need for a consistent, efficient, and reliable QA methodology specifically tailored for RapidArc to validate treatment plans before delivery to patients.

Methods

The researchers developed a multi-faceted QA approach:

  • 2D Diode Array Measurements: They utilized the MapCHECK device, a 2D diode array, embedded in the MapPHAN 5 phantom at a depth of 5 cm water equivalent. This setup allowed for planar dose distribution measurements in both coronal and sagittal planes.
  • Ion Chamber Measurements: For point dose verification, an Exradin A16 ion chamber was used within a cylindrical QUASAR phantom. Six specific locations within the phantom were chosen to represent both high-dose and low-dose regions.
  • Independent MU Calculation: To verify the number of monitor units (MUs) calculated by the treatment planning system (Eclipse), they employed independent software, RadCalc.
  • Phantom Modeling: Crucially, they meticulously modeled the treatment couch and rails within the treatment planning system for phantom calculations to accurately account for beam attenuation, a factor often simplified or ignored in standard IMRT QA.
  • Agreement Metrics: The agreement between calculated and measured doses was assessed using two primary metrics:
  • Distance-to-Agreement (DTA): Measures the spatial difference between points of equal dose.
  • Gamma Index: A more comprehensive metric that considers both dose difference and spatial distance, providing a pass/fail criterion. They used a 3%/3 mm criterion with a 10% dose threshold (TH).
  • RadCalc MU Verification Strategy: For MU calculations, they initially used the average surface-to-source distance (SSD) from Eclipse. When discrepancies with RadCalc exceeded 5%, they implemented a strategy of dividing the arc into nine partial arcs for more accurate MU estimation.

Datasets

The study evaluated eleven RapidArc patients, including:

  • Four prostate patients
  • One prostate cone down patient
  • Two prostate bed patients
  • One trachea patient
  • Three GYN patients

The QA measurements were performed using these patient plans. No new benchmark datasets were introduced; rather, the study focused on validating existing patient treatment plans.

Key Insights and Ideas

  • Importance of Heterogeneity Corrections: The study highlighted that including couch structures and performing heterogeneous calculations in the phantom significantly improved the agreement between measurements and calculations compared to homogeneous calculations. This underscores the need to accurately model the phantom environment for reliable QA.
  • Gamma Index Superiority: While both DTA and gamma index showed good agreement, the gamma index approach consistently yielded slightly higher agreement percentages, suggesting it might be a more sensitive metric for RapidArc QA.
  • Strategic MU Verification: The approach of dividing arcs into partial plans for RadCalc MU verification proved effective in reducing discrepancies when initial calculations showed significant differences, demonstrating a practical solution for improving MU accuracy.
  • Consistency Across Sites and Anatomies: The methodology yielded good results across a variety of treatment sites and patient anatomies, suggesting its broad applicability.

Key Results

  • MapCHECK/MapPHAN 5 Agreement:
    • Average agreement for the DTA approach was 94.4%.
  • Average agreement for the gamma index approach was 96.3%.
  • QUASAR Phantom Agreement:
    • In high-dose areas for prostate cases, the discrepancy between calculations and ion chamber measurements was within 4.5%.
  • RadCalc MU Agreement:
    • After implementing the partial arc plan strategy for cases with >5% discrepancy, the agreement between RadCalc and Eclipse MUs was reduced to within ~4%.

Limitations and Future Work

  • Dose Threshold Investigation: The authors noted that a higher dose threshold (e.g., 20% instead of 10%) might be more appropriate for analysis and plan to investigate this further.
  • QUASAR Phantom Usage: QUASAR phantom measurements were performed for only three patients, suggesting this aspect of the QA could be expanded.
  • Plane Selection for MapCHECK: The authors plan to determine the most appropriate plane (coronal or sagittal) for MapCHECK measurements based on treatment site to optimize efficiency.
  • Future Detector Development: They anticipate that future, more advanced detectors will further enhance the capabilities for RapidArc QA.
  • Software Upgrades: The paper mentions that future software upgrades (e.g., allowing simultaneous optimization for multiple arcs) are expected to further reduce planning and QA time, making it comparable to routine IMRT QA.
  • Body Contour Import: Future RadCalc software is expected to import body contours, which should improve SSD estimation and agreement with Eclipse calculations.

Summary updated

Abstract

With the commercial introduction of the Varian RapidArc, a new modality for treatment planning and delivery, the need has arisen for consistent and efficient techniques for performing patient-specific quality assurance (QA) tests. In this paper we present our methodology for a RapidArc treatment plan QA procedure. For our measurements we used a 2D diode array (MapCHECK) embedded at 5 cm water equivalent depth in MapPHAN 5 phantom and an Exradin A16 ion chamber placed in six different positions in a cylindrical homogeneous phantom (QUASAR). We also checked the MUs for the RapidArc plans by using independent software (RadCalc). The agreement between Eclipse calculations and MapCHECK/MapPHAN5 measurements was evaluated using both absolute distance-to-agreement (DTA) and gamma index with 10% dose threshold (TH), 3% dose difference (DD), and 3 mm DTA. The average agreement was 94.4% for the DTA approach and 96.3% for the gamma index approach. In high-dose areas, the discrepancy between calculations and ion chamber measurements using the QUASAR phantom was within 4.5% for prostate cases. For the RadCalc calculations, we used the average SSD along the arc; however, for some patients the agreement for the MUs obtained with RadCalc versus Eclipse was inadequate (discrepancy > 5%). In these cases, the plan was divided into partial arc plans so that RadCalc could perform a better estimation of the MUs. The discrepancy was further reduced to within ~4% using this approach. Regardless of the variation in prescribed dose and location of the treated areas, we obtained very good results for all patients studied in this paper.
BibTeX
@article{iftimia2010quality,
  author = {Ileana Iftimia and Eileen T. Cirino and Li Xiong and Herbert W. Mower},
  title = {{Quality assurance methodology for Varian RapidArc treatment plans}},
  journal = {Journal of Applied Clinical Medical Physics},
  year = {2010},
  doi = {10.1120/jacmp.v11i4.3164},
}
Figure